Copyright
©2009 The WJG Press and Baishideng.
World J Gastroenterol. Sep 14, 2009; 15(34): 4278-4283
Published online Sep 14, 2009. doi: 10.3748/wjg.15.4278
Published online Sep 14, 2009. doi: 10.3748/wjg.15.4278
Table 2 Patient characteristics
| Characteristics | n |
| Median age (Range) (yr) | 62 (51-75) |
| Sex | |
| Male | 7 |
| Female | 5 |
| ECOG performance status | |
| 0–1 | 8 |
| 2 | 4 |
| CEA level (range) (ng/mL) | 882 (21-6327) |
| Primary site | |
| Colon | 10 |
| Rectum | 2 |
| Sites of metastasis | |
| Liver | 9 |
| Lung | 7 |
| Lymph nodes | 6 |
| Others | 5 |
| K-Ras status | |
| Wild-type | 9 |
| Mutated | 3 |
- Citation: Ghiringhelli F, Guiu B, Chauffert B, Ladoire S. Sirolimus, bevacizumab, 5-Fluorouracil and irinotecan for advanced colorectal cancer: A pilot study. World J Gastroenterol 2009; 15(34): 4278-4283
- URL: https://www.wjgnet.com/1007-9327/full/v15/i34/4278.htm
- DOI: https://dx.doi.org/10.3748/wjg.15.4278